Renal Cell Cancer Update
Home About RCCU Other Tumor Types About us Contact Us
Audio Title
User support
  To listen to individual tracks, click on the headphone.
To download tracks, right-click on the one you wish to download.
Motzer, MD Robert J Motzer, MD
Attending Physician
Genitourinary Oncology Section
Memorial Sloan-Kettering Cancer Center
New York, New York

  Click here to download the entire interview  
Track 1 Evolution of the treatment of renal cell carcinoma (RCC)
Track 2 Initial study of bevacizumab in metastatic renal cell carcinoma (mRCC)
Track 3 Clinical development of the multitargeted tyrosine kinase inhibitor (TKI) sorafenib in mRCC
Track 4 Clinical development of the multitargeted TKI sunitinib in mRCC
Track 5 mTOR inhibitor temsirolimus in poor-risk mRCC
Track 6 Clinical trials of first-line interferon alpha-2b with or without bevacizumab for mRCC

Track 7 Risk stratification for patients with mRCC
Track 8 Temsirolimus for poor-risk mRCC
Track 9 Selection of second-line therapy for patients with poor-risk mRCC
Track 10 Activity of single-agent bevacizumab in mRCC
Track 11 Side effects of sunitinib and sorafenib
Track 12 Clinical trials combining bevacizumab with other targeted agents in mRCC
Track 13 Cytoreductive nephrectomy in patients with mRCC
Track 14 Role of metastectomy in mRCC
Track 15 Clinical impact of recent advances with targeted therapies in RCC
Track 16 Clinical and biologic predictors of response to targeted therapies in RCC
George, MD
Daniel J George, MD
Associate Professor of Medicine and Surgery
Director of Genitourinary Oncology
Duke Medical Center
Durham, North Carolina

  Click here to download the entire interview  
Track 1 Dosing, scheduling and tolerability of the multikinase inhibitors
Track 2 Development of bevacizumab for RCC
Track 3 Balancing benefits and toxicities of targeted agents in the treatment of mRCC
Track 4 Interactive effect of interferon alpha-2b and bevacizumab on toxicity and efficacy
Track 5 Role of risk stratification in therapy selection for mRCC

Track 6 Effectiveness of the mTOR inhibitor temsirolimus in poor-risk mRCC
Track 7 Side effects of temsirolimus
Track 8 Clinical implications of pneumonitis associated with mTOR inhibitors
Track 9 Tolerability of temsirolimus in patients with previously treated disease
Track 10 Efficacy of temsirolimus in good-risk RCC
Track 11 Anti-angiogenic activity of temsirolimus
Track 12 Clinical algorithm for the treatment of mRCC
Track 13 Rationale and caveats for combining biologic agents in RCC
Track 14 Toxicities observed with bevacizumab/interferon alpha-2b
Track 15 Mechanisms and management of anti-VEGF-associated hypertension
Track 16 Management of bevacizumab-associated proteinuria
Track 17 Bevacizumab and epistaxis
Track 18 Potential direct antitumor effects of anti-VEGF targeted therapies
Amato, MD Robert J Amato, DO
Medical Director, Genitourinary Oncology Program
The Methodist Hospital Research Institute
Houston, Texas

  Click here to download the entire interview  
Track 1 Risk-benefit considerations in comparing bevacizumab/interferon to sunitinib and sorafenib
Track 2 Second-line therapy after sunitinib
Track 3 Tolerability of sunitinib or sorafenib
Track 4 Study of intrapatient dose-escalated sorafenib for patients with mRCC
Track 5 Hypertension associated with bevacizumab/TKI combination therapy in clinical trials
Track 6 Rationale for investigating the combination of mTOR inhibitors and TKIs

Track 7 Relationship between dosing and scheduling of the TKIs and therapeutic efficacy
Track 8 TKI-associated hypothyroidism in RCC
Track 9 Clinical trial of sunitinib/interferon alpha-2a and erlotinib in papillary RCC
Track 10 Systemic therapy for papillary RCC
Track 11 Proportion of patients with RCC treated with adjuvant therapy
Track 12 Historical evolution of adjuvant clinical trials in RCC
Track 13 Patterns of tumor progression in RCC
Track 14 Patient acceptance of long-term adjuvant therapy with biologic agents
Track 15 Time course of recurrence in RCC
Track 16 Role of nephrectomy in mRCC
Track 17 Wound-healing issues with biologic agents in RCC
Track 18 Role of interleukin-2 in RCC
Dutcher, MD Janice P Dutcher, MD
Professor of Medicine, New York Medical College
Associate Director for Clinical Affairs
Our Lady of Mercy Cancer Center
Bronx, New York

  Click here to download the entire interview  
Track 1 Temsirolimus, interferon alpha or the combination as first-line therapy for poor-risk mRCC
Track 2 Potential mechanism of action of temsirolimus in RCC
Track 3 AVOREN trial: Interferon alpha-2a with or without bevacizumab as first-line therapy for mRCC
Track 4 Bevacizumab monotherapy and stable disease
Track 5 Challenges in evaluating combination biologic therapies in RCC
Track 6 Clinical algorithm for the treatment of mRCC

Track 7 Side effects and tolerability of interleukin-2
Track 8 Potential mechanisms of action of immunotherapy in RCC
Track 9 Use of bevacizumab monotherapy
Track 10 Dose adjustments and management of toxicity in patients undergoing targeted therapies
Track 11 Selection of second-line therapy in mRCC
Track 12 New developments in the management of TKI-associated hand-foot syndrome
Track 13 Dose reductions to manage TKI-associated toxicities
Track 14 Dose escalation of sorafenib in mRCC
Track 15 Ongoing adjuvant trials in RCC

Track 16 Use of chemotherapy for patients with rapidly progressing mRCC
Track 17 Case discussion: A septuagenarian with small, bilateral mRCC lung nodules and subsequent brain metastases with rapid symptom relief from sunitinib
Track 18 Management of the primary tumor in patients with concurrent mRCC

Terms of Use and General Disclaimer | Privacy Policy
Copyright © 2008 Research To Practice. All Rights Reserved.
Previous issues User support